Find Dr. Yardley's phone number, address, insurance information, hospital affiliations and more. 1840 Medical Center Parkway, Suite 100 Peacock NW, Bearden J, Schnell F, White M, Greco FA, Burris HA, Barton JH, Hainsworth JD, Spigel DR, Yardley DA. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). You can also search by physician, practice, or hospital name. Irinotecan, carboplatin, and imatinib in extensive stage small cell lung cancer: A phase II trial of the Minnie Pearl Cancer Research Network. Phone +1 615-329-0570. All Rights Reserved. Tennessee Oncology | Website design by Lam.Agency. Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study. Click here to learn more about our methodology. Dr. Todd M. Bauer, MD | Nashville, TN | Oncologist | US News Doctors Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. Health Tip: Exercising After Breast Cancer, Lisa Esposito, Elaine K. Howley and Payton SyAug. Dr. Dana Thompson, MD is a medical oncology specialist in Nashville, TN and has over 34 years of experience in the medical field. Guest pick up and drop off is at the entrance on 335 24 th Avenue North. Hospital Affiliations. THE BEST 10 Oncologist in Nashville, TN - Yelp Dr. Denise Yardley, MD - Medical Oncology Specialist in Nashville, TN . Phase II study of gemcitabine (G) and bevacizumab (B) as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer (MBC). Tennessee Oncology, Nashville, TN, 37203. Rating. Cancer surgeons, or surgical oncologists, remove tumors, while medical oncologists treat cancers with chemotherapy. Denise A. Yardley, Peter A. Kaufman, Weidong Huang, Lea Krekow, Michael Savin, William E Lawler, Stephen Zrada, Alexander Starr, Harvey Einhorn, Lee S. Schwartzberg, John W Adams, Yolanda Lie, A. Paquet, Jeff Sperinde, Mojgan Haddad, Steve Anderson, Marlon Brigino, Rick L. Pesano, Michael Bates, Jodi Weidler, Linda D. Bosserman. When you visit your doctor, asking the right questions can empower you to take charge of your health. This provider currently accepts 44 insurance plans including Medicare and Medicaid. per week. Copyright 2023 Healthgrades Marketplace, LLC, Patent US Nos. Miranda FT, Spigel DR, Hainsworth JD, Thompson DS, Yardley DA, Burris HA, Litchy S, Shrader M, Hon JK, Corso SW, Greco FA. A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignancies. During life-changing events like childbirth and death, a doula can help you navigate the emotional and physical ups and downs. These are the promising new therapies and research findings in the fight against Alzheimer's disease. It can occur in the glands, ducts or tissue. FAX: 615-444-0492 Contact: thesurgicalclinics.com/dr. Yardley DA, Greco FA, Burris HA, Peacock NW, White M, Raefsky E, Thompson DS, Barton JH, Spigel DR, Hainsworth JD. Oncologists diagnose and treat cancers of all types. Aetna AWH NJ Choice POS II MultiTier - Standard Savings, Aetna EPO and Open Access Aetna Select Texas Health, Aetna Innovation Health Aetna Premier Care Network Plus, 1211 Medical Center Dr, Nashville, TN 37232, 2004 Hayes st Ste 720, Nashville, TN 37203, 300 20th Ave N Ste 601, Nashville, TN 37203, 2004 HAYES ST STE 360, NASHVILLE, TN 37203, 2004 Hayes St Ste 310, Nashville, TN 37203, Obstetrician-Gynecologists, Nashville, TN. Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. Phase I. Denise A. Yardley, Lowell L. Hart, Anne Favret, Sibel Blau, Sami Diab, Donald A. Richards, Joseph A. Sparano, J. Thad Beck, Paul Richards, Patrick J. Dr. Yardley's office is located at Tennessee Oncology Collections Medical Records Specialist Job in Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study. John D. Hainsworth, Patrick B. Murphy, Jose R. Alemar, Brooke R. Daniel, Robyn R. Young, Denise A. Yardley, HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physicians choice plus trastuzumab in patients with previously treated, anthracycline-nave, HER2-positive, locally advanced/metastatic breast cancer, Kathy D. Miller, Javier Cortes, Sara A. Hurvitz, Ian E. Krop, Debu Tripathy, Sunil Verma, Kaveh Riahi, Joseph G. Reynolds, Thomas Wickham, Istvn Molnr, Denise A. Yardley. Dr. Merriman does not have any hospital affiliations listed. Currently. Submission of this form is subject to Healthgrades, Help Millions of people find the right doctor and care they need, Get immediate care and visit with providers from the comfort of your home, or anywhere, Urgent care centers can be faster and cheaper for situations that are not life threatening, Doctors and patients discuss the latest medical treatments and health tips, Search prescription drugs for why theyre used, side effects and more, Back and Neck Surgery (Except Spinal Fusion). Please enter a valid 5-digit Zip Code. White, John D. Hainsworth. Explore Map. Efficacy of Margetuximab vs Trastuzumab in Patients with Pretreated ERBB2-Positive Advanced Breast Cancer. Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Nashville, TN 37205 Providers Overview Location Reviews Providers Dr. Todd Bauer, MD Hematology 9 Ratings On staff at Tristar Centennial Medical Center Dr. Johanna Bendell, MD Medical Oncology 13 Ratings Established 1976 in Nashville, Tennessee Oncology's mission remains unchanged: To provide access to high quality cancer care and the expertise of clinical research for all patients at. Here are the best hospitals in Florida for receiving cancer treatment. Brufsky A, Valero V, Tiangco B, Dakhil SR, Brize A, Duenne AA, Bousfoul N, Rugo HS, Yardley DA, Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER, Adam Brufsky, Musa Mayer, Hope S. Rugo, Peter A. Kaufman, Elizabeth Tan-Chiu, Debasish Tripathy, Iulia Cristina Tudor, L. Wang, Melissa Brammer, Mona Shing, Marianne Ulcickas Yood, Denise A. Yardley. Medicare supplement Plans F and G have been popular choices for Medigap coverage. Our 75 medical. Our growing number of locations may mean that expert care is closer than you think. Sarah Cannon Clinical Trials | Sarah Cannon TENNESSEE ONCOLOGY - 250 25th Ave N, Nashville, Tennessee - Yelp Lunin SD, Spigel DR, Hainsworth JD, Waterhouse DM, Infante JR, Yardley DA, Burris HA, Vazquez ER, Farley C, Greco FA. Ward, Aruna Mani, Mythili Shastry, L Finney, Laura M. DeBusk, John D. Hainsworth, Cabazitaxel Plus Lapatinib as Therapy for HER2 + Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose-finding Study, Denise A. Yardley, Lowell L. Hart, Patrick J. King, Kornelia Polyak, Franziska Michor, Eric P. Winer, Ian E. Krop. Denise A Yardley, Adam Brufsky, Robert E Coleman, Pierfranco F Conte, Javier Cortes, Stefan Glck, Jean-Mark A Nabholtz, Joyce O'Shaughnessy, Robert M Beck, Amy Ko, Markus F Renschler, Debora Barton, Nadia Harbeck, Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial, Edith A. Perez, Ahmad Awada, Joyce O'Shaughnessy, Hope S. Rugo, Chris Twelves, SeockAh A Im, Patricia Gmez-Pardo, Lee S. Schwartzberg, Vronique Diras, Denise A. Yardley, David Potter, Audrey Mailliez, Alvaro Moreno-Aspitia, Jin Seok Ahn, Carol Zhao, Ute Hoch, Mary Tagliaferri, Alison L. Hannah, Javier Cortes, A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score, Denise A. Yardley, N. W. Peacock, Mythili Shastry, Howard A. Burris, Rebecca Bechhold, C Hendricks, Carl N. Yoshizawa, Amy P. Sing, John D. Hainsworth, Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute, Denise A. Yardley, Linda D. Bosserman, Joyce O'Shaughnessy, William N. Harwin, Susan Kay Morgan, Victor M. Priego, N. W. Peacock, J. David Bass, Howard A. Burris, John D. Hainsworth. Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial. Job. Melody A. Cobleigh, Denise A. Yardley, Adam Brufsky, Hope S. Rugo, Sandra M. Swain, Peter A. Kaufman, Debu Tripathy, Sara A. Hurvitz, Joyce O'Shaughnessy, Ginny Mason, Vincent Antao, Haocheng Li, Laura Chu, Mohammad Jahanzeb, Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy, Denise A. Yardley, N. W. Peacock, Brooke R. Daniel, Betrand Anz, David C. Molthrop, Sonalee K. Shroff, Robyn R. Young, Aleksander Jankov, Amy Vander Woude, Mythili Shastry, Johanna Pasek, Laura M. DeBusk, John D. Hainsworth. Correlation of SPARC, ER, PR, and HER2 tumor with progression-free survival from a phase II neoadjuvant trial of gemcitabine, epirubicin, and nab-paclitaxel. Peter A. Kaufman, Kenneth J. Bloom, Howard A. Burris, Julie R. Gralow, Musa Mayer, Mark D. Pegram, Hope S. Rugo, Sandra M. Swain, Denise A. Yardley, Miu Chau, Deepa Lalla, Bongin Yoo, Melissa Brammer, Charles L. Vogel, Healthcare Resource Use and Expenditures among Metastatic Breast Cancer Patients Treated with HER2-Targeted Agents, Nicole Meyer, Yanni Hao, Xue Song, Nianwen Shi, William Johnson, Jaqueline Willemann Rogerio, Denise A. Yardley, Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER, Denise A. Yardley, Debu Tripathy, Adam Brufsky, Hope S. Rugo, Peter A. Kaufman, Musa Mayer, Jessica F. Magidson, Bongin Yoo, Cheng Quah, M. Ulcickas Yood, Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer, Denise A. Yardley, Peter A. Kaufman, Adam Brufsky, Marianne Ulcickas Yood, Hope S. Rugo, Musa Mayer, Cheng Quah, Bongin Yoo, Debu Tripathy. Nashville, TN 37203 Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib+endocrine therapyendocrine therapy alone in patients with HR+/HER2- early breast cancer. A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer, Olivier Rixe, Sandra X. Franco, Denise A. Yardley, Stephen R. D. Johnston, Miguel Martin, Banu Arun, Stephen P. Letrent, Hope S. Rugo, Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer, Nan Lin, Vronique Diras, Devchand Paul, Dominique Lossignol, Christos Christodoulou, Hans-Joachim Stemmler, Henri Roch, Minetta C. Liu, Richard Greil, Eva Ciruelos, Sibylle Loibl, Stefania Gori, Andrew M Wardley, Denise A. Yardley, Adam Brufsky, Joanne L. Blum, Stephen D. Rubin, Bernie Dharan, Klaudia Steplewski, Denise Zembryki, Cristina Oliva, Debasish F. Roychowdhury, Paolo Paoletti, Eric P. Winer. Foster, Denise A. Yardley, Richard B. Gaynor, Raheela Ashfaq. . Kathryn J. Ruddy, Yue Zheng, Nabihah Tayob, Jiani Hu, Chau T. Dang, Denise A. Yardley, Steven J. Isakoff, Vicente Valero, Meredith Faggen, Therese M. Mulvey, Ron Bose, Tal Sella, Douglas Weckstein, Antonio C. Wolff, Katherine E. Reeder-Hayes, Hope S. Rugo, Bhuvaneswari Ramaswamy, Dan Sayam Zuckerman, Lowell L. Hart, Vijayakrishna K. Gadi, Michael Constantine, Kit Cheng, Frederick Briccetti, Bryan P. Schneider, A. Merrill Garrett, P. Kelly Marcom, Kathy S. Albain, Patricia DeFusco, Nadine Tung, Blair Ardman, Rita Nanda, Rachel C. Jankowitz, Mothaffar F. Rimawi, Vandana G. Abramson, Paula R. Pohlmann, Catherine Van Poznak, Andres Forero-Torres, Minetta C. Liu, Shoshana M. Rosenberg, Michelle Demeo, Harold J. Burstein, Eric P. Winer, Ian E. Krop, Ann H. Partridge, Sara M. Tolaney, Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial, Sara M. Tolaney, Nabihah Tayob, Chau T. Dang, Denise A. Yardley, Steven J. Isakoff, Vicente Valero, Meredith Faggen, Therese M. Mulvey, Ron Bose, Jiani Hu, Douglas Weckstein, Antonio C. Wolff, Katherine E. Reeder-Hayes, Hope S. Rugo, Bhuvaneswari Ramaswamy, Dan Sayam Zuckerman, Lowell L. Hart, Vijayakrishna K. Gadi, Michael Constantine, Kit Cheng, Frederick Briccetti, Bryan P. Schneider, Audrey Merrill Garrett, Kelly Marcom, Kathy S. Albain, Patricia DeFusco, Nadine Tung, Blair Ardman, Rita Nanda, Rachel C. Jankowitz, Mothaffar F. Rimawi, Vandana G. Abramson, Paula R. Pohlmann, Catherine Van Poznak, Andres Forero-Torres, Minetta C. Liu, Kathryn J. Ruddy, Yue Zheng, Shoshana M. Rosenberg, Richard D. Gelber, Lorenzo Trippa, William T. Barry, Michelle Demeo, Harold J. Burstein, Ann H. Partridge, Eric P. Winer, Ian E. Krop, Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (METRIC): a randomized multicenter study, Linda T. Vahdat, Peter Schmid, Andres Forero-Torres, Kimberly L. Blackwell, Melinda L. Telli, Michelle E. Melisko, Volker Mbus, Javier Cortes, Alberto J. Montero, Cynthia X. Ma, Rita Nanda, Gail S. Wright, Yi He, Thomas Hawthorne, Rebecca G. Bagley, Abdel-Baset Halim, Christopher D. Turner, Denise A. Yardley. Preparing for your first cancer appointment can be overwhelming. Visceral Disease in Patients With Metastatic Breast Cancer: Efficacy and Safety of Treatment With Ixabepilone and Other Chemotherapeutic Agents, Tracheoesophageal Fistula Formation in Patients With Lung Cancer Treated With Chemoradiation and Bevacizumab, David R. Spigel, John D. Hainsworth, Denise A. Yardley, Eric L. Raefsky, Jeffrey Patton, N. W. Peacock, C. Farley, Howard A. Burris, F. Anthony Greco. Sara M. Tolaney, William T. Barry, Chau T. Dang, Denise A. Yardley, Beverly Moy, P. Kelly Marcom, Kathy S. Albain, Hope S. Rugo, Matthew J. Ellis, Iuliana Shapira, Antonio C. Wolff, Lisa A. Carey, Beth Overmoyer, Ann H. Partridge, Hao Guo, Clifford A. Hudis, Ian E. Krop, Harold J. Burstein, Eric P. Winer, Amrubicin as second- or third-line treatment for women with metastatic HER2-negative breast cancer: a Sarah Cannon Research Institute phase 1/2 trial, Denise A. Yardley, Eric L. Raefsky, John D. Hainsworth, Howard A. Burris, Victor M. Priego, Alejandro A. Inclan, Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer, Joyce O'Shaughnessy, Lee S. Schwartzberg, Michael A. Danso, Kathy D. Miller, Hope S. Rugo, Marcus Neubauer, Nicholas J. Robert, Beth A. Hellerstedt, Mansoor N. Saleh, Paul Richards, Jennifer M. Specht, D. A. Yardley, Robert W. Carlson, Richard S. Finn, Eric Charpentier, Ignacio Garcia-Ribas, Eric P. Winer. Tennessee Oncology, one of the nation's largest, community-based cancer care specialists, is home to one of the leading clinical trial networks in the country. Dr. Jack Erter, MD, Oncology | Nashville, TN | WebMD Romualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, Chau Dang, Denise A Yardley, Steven J Isakoff, Vicente Valero, Meredith Faggen, Therese Mulvey, Ron Bose, Jiani Hu, Douglas Weckstein, Antonio C Wolff, Katherine Reeder-Hayes, Hope S Rugo, Bhuvaneswari Ramaswamy, Dan Zuckerman, Lowell Hart, Vijayakrishna K Gadi, Michael Constantine, Kit Cheng, Frederick Briccetti, Bryan Schneider, Audrey Merrill Garrett, Kelly Marcom, Kathy Albain, Patricia DeFusco, Nadine Tung, Blair Ardman, Rita Nanda, Rachel C Jankowitz, Mothaffar Rimawi, Vandana Abramson, Paula R Pohlmann, Catherine Van Poznak, Andres Forero-Torres, Minetta Liu, Kathryn J Ruddy, Yue Zheng, Shoshana M Rosenberg, Richard D Gelber, Lorenzo Trippa, William Barry, Michelle DeMeo, Harold Burstein, Ann Partridge, Eric P Winer, Ian Krop, Sara M Tolaney. Phase II trial of high-dose weekly topotecan in patients with relapsed small-cell lung cancer (SCLC). This content is not available in your current region. Dr. Dana Thompson, MD - Medical Oncology Specialist in Nashville, TN
28101 Avenue Of The Giants Redcrest, Ca 95569, The New School Admission Hub Log In, Plattsburgh, Ny Events This Weekend, Foundations Learning Center, Nau Office Of Student Lifeluke Combs Edmonton Schedule, Articles T